Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Last Close
Mar 20  •  04:00PM ET
0.3420
Dollar change
-0.0187
Percentage change
-5.18
%
Index- P/E- EPS (ttm)-0.26 Insider Own0.00% Shs Outstand159.13M Perf Week-11.40%
Market Cap54.41M Forward P/E- EPS next Y-0.04 Insider Trans- Shs Float- Perf Month-20.83%
Enterprise Value13.62M PEG- EPS next Q-0.00 Inst Own42.21% Short Float- Perf Quarter-82.19%
Income-42.05M P/S106.69 EPS this Y23.33% Inst Trans-31.85% Short Ratio0.91 Perf Half Y-80.68%
Sales0.51M P/B1.33 EPS next Y-4.35% ROA-68.77% Short Interest13.76M Perf YTD-17.93%
Book/sh0.26 P/C1.33 EPS next 5Y-9.14% ROE-82.55% 52W High3.05 -88.79% Perf Year-86.64%
Cash/sh0.26 P/FCF- EPS past 3/5Y8.97% 38.96% ROIC-102.78% 52W Low0.20 71.00% Perf 3Y-53.78%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin73.60% Volatility8.84% 8.00% Perf 5Y-91.47%
Dividend TTM- EV/Sales26.71 EPS Y/Y TTM9.88% Oper. Margin-8001.44% ATR (14)0.04 Perf 10Y-
Dividend Ex-Date- Quick Ratio10.46 Sales Y/Y TTM- Profit Margin-8307.95% RSI (14)33.55 Recom1.71
Dividend Gr. 3/5Y- - Current Ratio10.46 EPS Q/Q-2.44% SMA20-11.73% Beta0.33 Target Price2.79
Payout- Debt/Eq0.00 Sales Q/Q- SMA50-22.41% Rel Volume0.12 Prev Close0.36
Employees39 LT Debt/Eq0.00 EarningsMar 19 BMO SMA200-78.12% Avg Volume15.13M Price0.34
IPOApr 24, 2019 Option/ShortYes / Yes EPS/Sales Surpr.22.48% -100.00% Trades Volume1,764,743 Change-5.18%
Date Action Analyst Rating Change Price Target Change
Dec-30-25Downgrade Jefferies Buy → Hold $0.50
Mar-27-25Initiated JP Morgan Overweight $7
Dec-06-24Initiated Jefferies Buy $7
Jun-13-24Initiated Robert W. Baird Outperform $8
Oct-13-23Resumed BTIG Research Buy $4
Aug-12-22Initiated Cantor Fitzgerald Overweight $4
May-05-21Initiated BTIG Research Buy $10
Apr-05-21Initiated Needham Buy $10
Mar-20-26 01:13AM
Mar-19-26 08:30AM
Mar-18-26 09:05AM
Mar-12-26 04:19AM
Mar-11-26 09:00AM
09:00AM Loading…
Feb-25-26 09:00AM
Feb-14-26 11:23AM
Feb-09-26 03:29AM
Feb-06-26 07:30AM
Jan-12-26 08:00AM
Dec-31-25 09:40AM
Dec-30-25 12:39PM
11:00AM
09:36AM
Dec-29-25 01:05PM
08:31AM Loading…
08:31AM
Nov-10-25 04:01PM
Aug-19-25 08:30AM
Aug-12-25 07:35AM
Aug-11-25 07:45AM
Jul-10-25 10:37AM
10:34AM
10:17AM
07:52AM
Jul-09-25 04:05PM
May-13-25 07:30AM
Apr-16-25 03:00PM
11:23AM
Mar-26-25 07:30AM
Mar-20-25 12:00PM
07:30AM Loading…
Mar-05-25 07:30AM
Feb-11-25 11:00AM
Feb-10-25 02:12PM
Jan-12-25 11:05AM
Jan-07-25 07:30AM
Dec-30-24 02:50PM
Dec-07-24 05:20AM
Dec-06-24 01:18PM
Nov-14-24 07:30AM
Nov-12-24 07:30AM
Oct-16-24 09:06AM
Sep-18-24 08:21AM
Sep-12-24 05:35PM
Aug-13-24 08:00AM
Jun-15-24 11:42PM
Jun-14-24 07:50AM
Jun-12-24 07:45AM
Jun-11-24 05:47PM
May-30-24 07:30AM
May-15-24 04:01PM
Apr-12-24 09:35AM
Apr-03-24 07:30AM
Mar-27-24 05:27PM
04:01PM
Mar-05-24 07:30AM
Feb-16-24 03:57AM
Jan-08-24 07:00AM
Dec-19-23 11:21AM
Nov-03-23 11:43AM
Oct-23-23 04:01PM
Oct-14-23 04:30PM
Oct-09-23 08:00AM
Sep-21-23 07:00AM
Sep-07-23 07:30AM
Aug-10-23 11:04PM
Aug-04-23 08:12AM
Jul-07-23 07:46AM
Jul-06-23 08:00AM
May-31-23 07:00AM
May-23-23 01:43PM
May-08-23 12:46PM
May-05-23 04:06PM
Apr-21-23 12:00PM
Apr-13-23 08:00AM
Mar-28-23 04:30PM
Mar-21-23 06:30AM
Feb-08-23 07:00AM
Jan-10-23 05:35AM
Nov-15-22 09:35AM
Nov-08-22 07:00AM
Nov-02-22 04:01PM
Oct-28-22 07:00AM
Oct-24-22 04:30PM
Oct-21-22 07:00AM
Oct-18-22 11:58AM
07:00AM
Oct-17-22 07:00AM
Oct-03-22 05:00PM
09:00AM
Sep-28-22 09:21AM
Sep-26-22 07:00AM
Sep-14-22 09:00AM
Sep-12-22 08:00AM
Sep-09-22 08:22PM
Aug-31-22 07:00AM
Aug-22-22 04:00AM
Jul-05-22 04:01PM
Jun-21-22 08:30AM
Jun-20-22 10:36AM
Jun-17-22 05:30PM
Mereo BioPharma Group Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. Its portfolio include Etigilimab (MPH-313), Alvelestat (MPH-966), Setrusumab (BPS-804), Navicixizumab (OMP-305B83), Acumapimod (BCT-197), and Leflutrozole (BGS-649). The company was founded by Denise Vera Scots-Knight, Charles Edward Sermon, Alastair Graham MacKinnon, and John P. Richard in March 10, 2015 and is headquartered in London, the United Kingdom.